Propulsion of Asthma Pipeline as Novel and Extensive 95+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
Asthma is a chronic disease that affects a substantial number of patients worldwide, including children, a number of pharmaceutical companies are involved in developing drugs for asthma. This involvement includes the development of novel therapies that being evaluated in different phases of development.
Key Takeaways from the Asthma Pipeline Report
- DelveInsight's asthma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for asthma treatment.
- Key asthma companies such as Mabpharm Limited,
Avillion LLP , GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics,Verona Pharma , MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals,Concentrx Pharmaceuticals ,Tetherex Pharmaceuticals , SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc,Hoffman-La-Roche ,Celltrion , Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences,Sunshine Guojian Pharmaceutical , Mabwell (Shanghai ) Bioscience, Kinaset Therapeutics,Akari Therapeutics , KLUS Pharma, Upstream Bio, LEO Pharma, and others are evaluating new asthma drugs to improve the treatment landscape. - Promising asthma pipeline therapies in various stages of development include CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others.
- In
February 2023 ,UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted an Innovation Passport under theInnovative Licensing and Access Pathway (ILAP) to dexpramipexole, an eosinophil lowering small molecule, that has recently entered Phase III clinical development. Dexpramipexole is beig developed by Areteia Therapeutics to inhibit the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. - In
February 2023 , Pulmatrix, Inc. announced that the first patient dosed in a Phase IIb trial evaluating safety and efficacy of PUR1900 in subjects with Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. PUR1900 is the company's iSPERSE-enabled dry powder formulation of itraconazole, developed for inhaled pulmonary delivery. The Phase II trial is designed as a randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy and duration of treatment with itraconazole, administered as a dry powder for inhalation (PUR1900). Endpoints include safety, tolerability, and potential efficacy outcomes in adult patients with asthma and ABPA. Olatec Therapeutics LLC inFebruary 2023 completed the$40 million Sanders Morris Harris ("SMH"). Participation in the round came from both existing investors as well as new investors identified by each ofSanders Morris Harris ,Advection Growth Capital , and the Company. Proceeds will be principally used to advance Olatec's lead compound, dapansutrile, into later-stage clinical development. Dapansutrile has also been observed to have anti-inflammatory properties and other promising activity in a broad spectrum of over 20 preclinical animal models, including arthritis, asthma, acute myocardial infarction (AMI), heart failure, contact dermatitis, multiple sclerosis, melanoma, pancreatic and breast cancers, spinal cord injury (SCI), Parkinson's and Alzheimer's disease.- In
January 2023 ,Avillion LLP , announced that theUS Food and Drug Administration (FDA) approved AstraZeneca's Airsupra (albuterol/budesonide, formerly known as PT027) for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS). - Upstream Bio, in
August 2022 , initiated a Phase Ib multiple ascending dose study of UPB-101 in asthma patients and successful dosing of the first patient. UPB-101 is a monoclonal antibody designed to block the thymic stromal lymphopoietin receptor (TLSPR) and thus inhibit TSLP-driven inflammation. TSLP is a cytokine and a key driver of inflammatory response in asthma and other allergic and inflammatory diseases.
Request a sample and discover the recent advances in asthma drug treatment @ Asthma Pipeline Report
The asthma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage asthma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the asthma clinical trial landscape.
Asthma Overview
Asthma is a chronic disease of the airways. Asthma is characterized by airway inflammation and spasm. Airways are tubes that transport air into and out of the lungs. Asthmatics cause the inside walls of the airways to become sore and swollen. Because of inflammation and tightening of the muscles surrounding the small airways, the airways in the lungs become narrow. Asthma symptoms include coughing, wheezing, shortness of breath, and chest tightness. Asthma symptoms differ from person to person. A person may have infrequent asthma attacks, have symptoms only when exercising, or have symptoms all of the time. Asthma symptoms are similar to those of many respiratory infections.
A careful clinical history is the first step in asthma diagnosis; identifying the characteristic symptoms and their duration, intensity, and relationship of symptoms with allergen and triggering agent; and the impact of these symptoms on quality of life.
Find out more about drugs for asthma @ New Asthma Drugs
A snapshot of the Asthma Pipeline Drugs mentioned in the report:
Drugs | Company | Phase | MoA | RoA |
MM09-MG01 | Phase III | Immunomodulators | Subcutaneous | |
BGF MDI | AstraZeneca | Phase III | Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists | Inhalation |
GSK3511294 | GlaxoSmithKline | Phase III | Interleukin 5 receptor antagonists | Subcutaneous |
FP 025 | Foresee Pharmaceuticals | Phase II | Matrix metalloproteinase 12 inhibitors | Oral |
ADX-629 | Aldeyra Therapeutics | Phase II | Aldehyde inhibitors | Oral |
610 | Phase II | Interleukin 5 inhibitor | Subcutaneous | |
EDP1867 | Evelo Biosciences, Inc. | Phase I | Bacteria replacements; Microbiome modulators | Oral |
CM-326 | Keymed Biosciences | Phase I | Thymic stromal lymphopoietin inhibitors; Thymic stromal lymphopoietin modulators | Subcutaneous |
9MW1911 | Phase I | Interleukin-33 inhibitors | Intravenous | |
Dapansutrile | Olatec Therapeutics | Preclinical | Inflammasome inhibitors; Interleukin 1 beta inhibitors; Interleukin 18 inhibitors; Interleukin inhibitors; NLRP3 protein inhibitors | Oral |
LNR 125.38 | Lanier Biotherapeutics | Preclinical | Interleukin-17 inhibitors | Intraperitoneal |
Learn more about the emerging asthma pipeline therapies @ Asthma Clinical Trials
Asthma Therapeutics Assessment
The asthma pipeline report proffers an integral view of asthma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Asthma Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
- Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Immunomodulators, Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists, Interleukin 5 receptor antagonists, Matrix metalloproteinase 12 inhibitors, Aldehyde inhibitors, Bacteria replacements; Microbiome modulators, Thymic stromal lymphopoietin inhibitors; Thymic stromal lymphopoietin modulators, Interleukin-33 inhibitors, Inflammasome inhibitors; Interleukin 1 beta inhibitors; Interleukin 18 inhibitors; Interleukin inhibitors; NLRP3 protein inhibitors, Interleukin-17 inhibitors
- Key Asthma Companies: Mabpharm Limited,
Avillion LLP , GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics,Verona Pharma , MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals,Concentrx Pharmaceuticals ,Tetherex Pharmaceuticals , SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc,Hoffman-La-Roche ,Celltrion , Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences,Sunshine Guojian Pharmaceutical , Mabwell (Shanghai ) Bioscience, Kinaset Therapeutics,Akari Therapeutics , KLUS Pharma, Upstream Bio, LEO Pharma, and others. - Key Asthma Pipeline Therapies: CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others.
Dive deep into rich insights for new drugs for asthma treatment; visit @ Asthma Medications
Table of Contents
1. | Asthma Pipeline Report Introduction |
2. | Asthma Pipeline Report Executive Summary |
3. | Asthma Pipeline: Overview |
4. | Analytical Perspective In-depth Commercial Assessment |
5. | Asthma Clinical Trial Therapeutics |
6. | Asthma Pipeline: Late Stage Products (Pre-registration) |
7. | Asthma Pipeline: Late Stage Products (Phase III) |
7.1 | BGF MDI: AstraZeneca |
8. | Asthma Pipeline: Mid Stage Products (Phase II) |
8.1 | GSK3511294: GlaxoSmithKline |
9. | Asthma Pipeline: Early Stage Products (Phase I) |
9.1 | CM-326: Keymed Biosciences |
10. | Asthma Pipeline Therapeutics Assessment |
11. | Inactive Products in the Asthma Pipeline |
12. | Company-University Collaborations (Licensing/Partnering) Analysis |
13. | Key Companies |
14. | Key Products in the Asthma Pipeline |
15. | Unmet Needs |
16. | Market Drivers and Barriers |
17. | Future Perspectives and Conclusion |
18. | Analyst Views |
19. | Appendix |
For further information on the asthma pipeline therapeutics, reach out @ Asthma Drug Treatment
Related Reports
Severe Asthma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key severe asthma companies, including AstraZeneca, Novartis, Sanofi, among others.
Asthma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key asthma companies, including GSK, AstraZeneca,
Severe Asthma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key severe asthma companies, including AstraZeneca, Novartis, Sanofi, among others.
Chronic Obstructive Pulmonary Disease Epidemiology Forecast
Chronic Obstructive Pulmonary Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the chronic obstructive pulmonary disease epidemiology trends.
Chronic Obstructive Pulmonary Disease Market
Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic obstructive pulmonary disease companies, including Sanofi,
Acute Respiratory Distress Syndrome Pipeline
Acute Respiratory Distress Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key acute respiratory distress syndrome companies, including Bayer,
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell
Related Healthcare Blogs
Emerging Therapies for Severe Asthma Treatment
Chronic Respiratory Disease Market
Promising Therapies in the ARDS Market
Rising Acute Respiratory Distress Syndrome Prevalence
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading
Connect with us on LinkedIn|Facebook|Twitter
Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services
Contact Us
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/propulsion-of-asthma-pipeline-as-novel-and-extensive-95-therapies-likely-to-enter-in-the-treatment-domain--delveinsight-301760769.html
SOURCE
